Targeting the mTOR signaling network for cancer therapy.

By Funda Meric-Bernstam, A. González-Angulo. Journal of Clinical Oncology, 2009

666 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. (2011, background): “In others, however, the response rates are less impressive, with the clinical outcome being to stabilize the disease rather than producing tumor regression (19).”
Role of AMPK-mTOR-Ulk1/2 in the Regulation of Autophagy: Cross Talk, Shortcuts, and Feedbacks (2011, background): “However, although mTOR signaling is frequently dysregulated in cancer, rapamycin analogs do not show any considerable activity as single agents in many tumor types and thus are often used in combination therapy (79).”
The PI3K pathway as drug target in human cancer. (2010, background): “The role for rapamycin analogs in the treatment of cancer has been extensively reviewed elsewhere and thus will not be discussed further.(30) In this review, we will discuss the potential therapeutic roles for other PI3K pathway inhibitors.”